TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas

Trial Details

NCT ID
NCT07082803
Phase
PHASE1
Sponsor
Treeline Biosciences, Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • TLN-121
  • TLN-254
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • St Louis, Missouri, United States|38.62727,-90.19789
  • New York, New York, United States|40.71427,-74.00597
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Disease Characteristics
  • Participant must have measurable disease at study entry
  • Participants must have one of the following histologically documented hematologic malignancies:
  • Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (DLBCL, NOS), Follicular lymphoma (FL) grade 3b, or transformed lymphoma from FL fol…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →